ArticleGynecologic oncology reports2026
Response to progestin-based therapy in endometrial intraepithelial neoplasia: An exploratory biomarker study.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: With the incidence of endometrial intraepithelial neoplasia (EIN) rising among premenopausal women, fertility-sparing management with progestin-based therapy is increasingly utilized, yet a substantial proportion of patients fail to respond. This study explored associations between baseline tissue biomarker expression and response to progestin-based therapy in premenopausal women with EIN. Methods: This was a single-institution retrospective cohort study of premenopausal women with EIN undergoing conservative management between March 2015 and December 2023. Immunohistochemical expression of progesterone receptor A (PR-A), progesterone receptor B (PR-B), and glucagon-like peptide-1 receptor (GLP-1R) was evaluated in pre-treatment and post-treatment endometrial biopsy specimens. Treatment response was dichotomized as complete response (CR) or progesterone resistance (PGR), defined as failure to achieve CR within 12 months of initiating progestin-based therapy. Associations between biomarker expression and treatment response were explored using descriptive and regression analyses. Results: Endometrial biopsies were analyzed from 28 premenopausal patients prior to the initiation of progestin-based therapy. Baseline PR-A expression was significantly lower among non-responders in both glandular and stromal compartments. A pre-treatment PR-A:PR-B ratio ≤ 1 was associated with progesterone resistance in glandular tissue, whereas pre-treatment GLP-1R expression was not significantly associated with treatment response. Post-treatment glandular GLP-1R expression differed between groups, with a higher proportion of high expression observed among non-responders (54.6% vs. 6.7%, Conclusion: In this exploratory cohort, baseline progesterone receptor expression patterns were associated with response to progestin-based therapy. These findings warrant validation in larger, prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.